LRMR
Price
$2.12
Change
-$0.12 (-5.36%)
Updated
May 9 closing price
Capitalization
135.74M
88 days until earnings call
SYRE
Price
$14.10
Change
+$1.24 (+9.64%)
Updated
May 9 closing price
Capitalization
849.89M
81 days until earnings call
Ad is loading...

LRMR vs SYRE

Header iconLRMR vs SYRE Comparison
Open Charts LRMR vs SYREBanner chart's image
Larimar Therapeutics
Price$2.12
Change-$0.12 (-5.36%)
Volume$786.83K
Capitalization135.74M
Spyre Therapeutics
Price$14.10
Change+$1.24 (+9.64%)
Volume$966.72K
Capitalization849.89M
LRMR vs SYRE Comparison Chart
Loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LRMR vs. SYRE commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a StrongBuy and SYRE is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (LRMR: $2.12 vs. SYRE: $14.10)
Brand notoriety: LRMR and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LRMR: 69% vs. SYRE: 135%
Market capitalization -- LRMR: $135.74M vs. SYRE: $849.89M
LRMR [@Biotechnology] is valued at $135.74M. SYRE’s [@Biotechnology] market capitalization is $849.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LRMR’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • LRMR’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, LRMR is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LRMR’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • LRMR’s TA Score: 4 bullish, 6 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than LRMR.

Price Growth

LRMR (@Biotechnology) experienced а -28.62% price change this week, while SYRE (@Biotechnology) price change was -6.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

LRMR is expected to report earnings on Aug 07, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($850M) has a higher market cap than LRMR($136M). SYRE YTD gains are higher at: -39.433 vs. LRMR (-45.220). LRMR has higher annual earnings (EBITDA): -73.44M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. LRMR (204M). SYRE has less debt than LRMR: SYRE (0) vs LRMR (5.36M). LRMR (0) and SYRE (0) have equivalent revenues.
LRMRSYRELRMR / SYRE
Capitalization136M850M16%
EBITDA-73.44M-208.57M35%
Gain YTD-45.220-39.433115%
P/E RatioN/A1.72-
Revenue00-
Total Cash204M603M34%
Total Debt5.36M0-
FUNDAMENTALS RATINGS
LRMR vs SYRE: Fundamental Ratings
LRMR
SYRE
OUTLOOK RATING
1..100
2922
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
6465
P/E GROWTH RATING
1..100
10077
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (21) in the null industry is somewhat better than the same rating for SYRE (76) in the Pharmaceuticals Major industry. This means that LRMR’s stock grew somewhat faster than SYRE’s over the last 12 months.

LRMR's Profit vs Risk Rating (100) in the null industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that LRMR’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's SMR Rating (93) in the Pharmaceuticals Major industry is in the same range as LRMR (100) in the null industry. This means that SYRE’s stock grew similarly to LRMR’s over the last 12 months.

LRMR's Price Growth Rating (64) in the null industry is in the same range as SYRE (65) in the Pharmaceuticals Major industry. This means that LRMR’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (77) in the Pharmaceuticals Major industry is in the same range as LRMR (100) in the null industry. This means that SYRE’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LRMRSYRE
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 2 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
89%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGRIX62.300.11
+0.18%
Fidelity Growth & Income
FRIEX16.670.03
+0.18%
Federated Hermes Emerging Markets Eq R6
PGPRX24.780.01
+0.04%
George Putnam Balanced R
WPSGX53.30-0.10
-0.19%
AB Concentrated Growth Advisor
AMGCX8.51-0.08
-0.93%
Alger Mid Cap Growth C

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with ERAS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then ERAS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
-5.36%
ERAS - LRMR
49%
Loosely correlated
N/A
SVRA - LRMR
49%
Loosely correlated
-11.18%
IMNM - LRMR
49%
Loosely correlated
-3.24%
IDYA - LRMR
47%
Loosely correlated
-4.18%
PRME - LRMR
46%
Loosely correlated
-1.52%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+9.64%
BEAM - SYRE
56%
Loosely correlated
+0.93%
APGE - SYRE
52%
Loosely correlated
-1.38%
IDYA - SYRE
52%
Loosely correlated
-4.18%
CGON - SYRE
52%
Loosely correlated
-1.62%
RCKT - SYRE
50%
Loosely correlated
-0.71%
More